Drug intelligence / Profile preview

BH0012

Development stage: Preclinical
Lead developer: Hanmi Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BH0012 is a preclinical-stage bispecific antibody developed by Beijing Hanmei Pharmaceutical (Beijing Hanmi Pharmaceutical) for the treatment of solid tumors. It is designed to simultaneously target Programmed Death-Ligand 1 (PD-L1) and CD47. By blocking the PD-1/PD-L1 axis, BH0012 aims to alleviate T-cell suppression, while its inhibition of the CD47-SIRPα interaction (the 'don't eat me' signal) enhances macrophage-mediated phagocytosis of tumor cells. This dual-targeting approach is intended to synergistically activate both the innate and adaptive immune systems against cancer.

Targets

CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on BH0012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BH0012.

Explore the full profile